OncoMatch/Clinical Trials/NCT04496349
A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHL
Is NCT04496349 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including APG-115 and APG-2575 for t-prolymphocytic leukemia.
Treatment: APG-115 · APG-2575 — The goal of this study is to evaluate the pharmacokinetics (PK), safety, and efficacy of APG-115 as a single agent or in combination with APG-2575 in patients with T-PLL and NHL.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Non-Hodgkin Lymphoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: any prior therapy
relapsed/refractory T-PLL who have active disease and have received at least one prior therapy
Cannot have received: MDM2 inhibitor
Patient previously treated with a murine double minute 2 (MDM2) inhibitor
Lab requirements
Blood counts
Absolute neutrophil count (ANC) ≥ 500/mm˄3; hemoglobin ≥ 60 g/L; platelet count ≥ 30,000/mm˄3
Kidney function
adequate organ function
Liver function
adequate organ function
Absolute neutrophil count (ANC) ≥ 500/mm˄3; hemoglobin ≥ 60 g/L; platelet count ≥ 30,000/mm˄3; Patients with adequate organ function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- MD Anderson · Houston, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify